Is There Less Aggressive Lipid Management in PAD Patients? - American College of Cardiology
For patients with peripheral artery disease (PAD), intensity of lipid-lowering therapy may be a "poor surrogate" for achieved LDL-cholesterol (LDL-C), as achieved LDL-C levels remain elevated for the majority of...
Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab
Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease....
Management of Dyslipidemia in Patients with Diabetes - touchENDOCRINOLOGY
Source : https://doi.org/10.17925/USE.2011.07.01.40
In association with the global spread of abdominal adiposity, the worldwide prevalence of type 2 diabetes continues to increase.1 This is one of the pivotal factors underscoring the projection that...
